Compare PI & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PI | TMDX |
|---|---|---|
| Founded | 2000 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 4.6B |
| IPO Year | 2011 | 2019 |
| Metric | PI | TMDX |
|---|---|---|
| Price | $99.79 | $114.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $176.38 | $154.00 |
| AVG Volume (30 Days) | 599.4K | ★ 857.9K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | N/A | ★ 4.87 |
| Revenue | $122,633,000.00 | ★ $605,494,000.00 |
| Revenue This Year | $4.79 | $24.12 |
| Revenue Next Year | $24.69 | $18.69 |
| P/E Ratio | ★ N/A | $23.20 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $60.85 | $62.42 |
| 52 Week High | $247.06 | $156.00 |
| Indicator | PI | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 39.72 | 33.52 |
| Support Level | $87.96 | $106.27 |
| Resistance Level | $123.33 | $131.86 |
| Average True Range (ATR) | 6.92 | 7.56 |
| MACD | 1.14 | -2.53 |
| Stochastic Oscillator | 32.95 | 8.97 |
Impinj Inc operates a platform that enables wireless connectivity to everyday items by delivering each item's identity, location, and authenticity to business and consumer applications. Its platform includes endpoint integrated circuits (ICs) product, a miniature radios-on-a-chip, which attach to and identify their host items; and connectivity layer that comprises readers, gateways, and reader ICs to wirelessly identify, locate, authenticate, and engage endpoints via RAIN, as well as provide power to and communicate bidirectionally with endpoint ICs. Geographically, the company has a business presence in the Americas, Asia Pacific, Europe, Middle East and Africa, of which key revenue is derived from the operations in the Asia Pacific region.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.